Global Prostate Cancer Market Size to Exceed USD 47.26 Billion by 2035 | CAGR of 9.54%

Global Prostate Cancer Market Size to Exceed USD 47.26 Billion by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Prostate Cancer Market Size is expected to Grow from USD 17.35 Billion in 2024 to USD 47.26 Billion by 2035, at a CAGR of 9.54% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Prostate Cancer Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines, Parp Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands), By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/prostate-cancer-market                   

The prostate cancer market encompasses the global system of diagnostics, therapies, and supportive care alternatives aimed at preventing, detecting, and treating prostate cancer. The market is affected by outcomes from clinical trials, regulatory approvals, reimbursement policies, and the adoption of new treatment approaches. It includes research institutions, hospitals, speciality clinics, and biopharmaceutical companies, with growth driven by the rising occurrence of diseases, ageing populations, and progress in precision medicine. Prostate cancer takes the lives of one in every forty-one men, ranking just after lung cancer. Despite being a severe disease, most men diagnosed with prostate cancer do not die from it. The therapeutic market for prostate cancer is affected by the rising prevalence of the disease, the adoption of advanced screening techniques and diagnostic tools, and governmental efforts to promote novel treatments for prostate cancer. Contemporary advancements such as computational biology and bioinformatics are assisting in the development of new therapies. Proteome profiling and genome sequencing are two techniques that industry players are employing to create improved treatments. The prostate cancer market faces challenges due to expensive treatments, reimbursement obstacles, and limited access in developing regions, despite significant innovation progress. Safety concerns, side effects, and regulatory delays affect patient compliance.

The AR-directed therapies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the drug class, the prostate cancer market is segmented into hormonal ADT, AR-directed therapies, cytotoxic agents, bone metastases, therapeutic vaccines, PARP inhibitors, kinase inhibitors, and PSMA-targeted radioligands. Among these, the AR-directed therapies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The growing use of apalutamide and enzalutamide in previously approved circumstances, as well as the anticipated label expansions in hormone-sensitive settings, will fuel the segment's growth.

The hormonal therapy segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the treatment, the prostate cancer market is divided into hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Among these, the hormonal therapy segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The predilection for hormonal medicines has been reinforced by their use in first-line therapy regimens. Treatment consistency and patient tolerability have contributed to the segment's dominance in clinical oncology practice.

Asia Pacific is expected to hold the majority share of the global prostate cancer market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global prostate cancer market during the forecast period. The market is expanding due to several factors, including cost-effective therapy, customised pharmaceuticals, technological advancements, a variety of treatment options, and the rising incidence of prostate cancer. Japan is a significant player in the Asia-Pacific market due to its ageing population and first-rate healthcare facilities.

Europe is anticipated to grow at the fastest pace in the global prostate cancer market during the forecast period. This is aided by a well-established oncology care infrastructure and a sizable patient population. Numerous national screening programs, universal healthcare, and simple access to state-of-the-art diagnostics have all contributed to growth in the field. Furthermore, effective reimbursement rules in significant areas like the UK, Germany, and France enable the rapid adoption of innovation in these crucial sectors.

Major vendors in the global prostate cancer market are Astellas Pharma Inc., AstraZeneca, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Clovis Oncology, Inc., Eli Lilly and Company, Exelixis, Inc., Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In June 2025, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) was revealed by Novartis. In patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), the Phase 3 PSMAddition trial shows a statistically significant and clinically relevant improvement in radiographic progression-free survival (rPFS).

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the prostate cancer market based on the below-mentioned segments:  

Global Prostate Cancer Market, By Drug Class

• Hormonal ADT
• AR-Directed Therapies
• Cytotoxic Agents
• Bone Metastases
• Therapeutic Vaccines
• Parp Inhibitors
• Kinase Inhibitors
• PSMA-Targeted Radioligands

Global Prostate Cancer Market, By Treatment

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Others

Global Prostate Cancer Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa